Raptor Falls On Failed Investigator-Run NASH Study
This article was originally published in Scrip
Executive Summary
Raptor Pharmaceuticals fell 37.5% on Sept. 14 to $7.52 per share after the Novato, California-based company revealed that RP103, a delayed-release version of its approved cystinosis drug Procysbi (cysteamine bitartrate) failed in a Phase IIb pediatric non-alcoholic steatohepatitis (NASH) clinical trial.
You may also be interested in...
Raptor Buy Bolsters Horizon's Orphan Business As Primary Care Foots The Bill
Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.